Therapy of an Animal Model of Human Gastric Cancer Using a Combination of Anti-erbB-2 Monoclonal Antibodies

Cancer Research

Volumn 52, Issue 10, 1992, Pages 2771-2776

  Di Fiore, Pier Paolo ^b   Song, Sun Uk ^a   Richter King, C ^a  

^a Molecular Oncology Inc ^*  (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; MONOCLONAL ANTIBODY; ONCOPROTEIN; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRAFT; CANCER IMMUNOTHERAPY; CANCER INHIBITION; COMPLEX FORMATION; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH CANCER; TUMOR CELL LINE; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR REGRESSION;

3T3 CELLS; ANIMAL; ANTIBODIES, MONOCLONAL; CELL DIVISION; COLORIMETRY; COMPARATIVE STUDY; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; SUPPORT, U.S. GOV'T, P.H.S.; TETRAZOLIUM SALTS; THIAZOLES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0026685034     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. King, C. R., Kraus, M. H., and Aaronson, S. A. Amplification of a novel c-erbB related gene in a human mammary carcinoma. Science (Washington DC), 229:974-976,1985.
2. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Washington DC), 235:177-182,1987.
3. Slamon, D. J., Godolophin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and Press, M. F. Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science (Washington DC), 244:707-712, 1989.
4. Yokota, J., Yamamoto, T., Toyoshima, K., Sugimura, T., Yamamoto, T., Terada, M., Battifora, H., and Cline, M. J. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet, 1:765-767,1986.
5. King, C. R., Swain, S. M., Porter, L., Steinberg, S. M., Lippman, M. E., and Gelman, E. P. Heterogenous expression of erbB-2 messenger RNA in human breast cancer. Cancer Res., 49:4185-4191,1989.
6. Schneider, P. M., Hung, M-C., Chiocca, S. M., Manning, J., Zhao, X., Fang, H., and Roth, J. A. Differential expression of the erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res., 49:4968-4971,1989.
7. Park, J., Rhim, J. S., Park, S., Kimm, S., and Kraus, M. Amplification, overexpression and rearrangement of the erbB-2 protooncogene in primary human stomach carcinomas. Cancer Res., 49:6605-6609,1989.
8. Wright, C., Angus, B., Nicholson, S., Sainsbury, J. R., Cairns, J., Gullick, W. J., Kelly, P., Harris, A. L., and Horne, C. H. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res., 49: 2087-2090,1989.
9. Tandon, A. K., Clark, G. M., Chamness, G. C., Ullrich, A., and McGuire, W. L. Her-2/neu oncogene protein and prognosis in breast cancer. J. Clin. Oncol., 7: 1120-1128,1989.
10. Paik, S., Hazan, R., Fisher, E. R., Sass, R. E., Fisher, B., Redmond, C., Schlessinger, J., Lippman, M. E., and King, C. R. Pathological findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J. Clin. Oncol., 8:103-112,1990.
11. Borg, A., Tandon, A. K., Sigurdsson, H., Clark, G. M., Femo, M., Fuqua, S. A. W., Killander, D., and McGuire, W. L. Her-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res., 50: 4332-4337, 1990.
12. Berchuck, A., Kamel, A., Whitaker, R., Kerns, B., Olt, G., Kinney, R., Soper, J. T., Dodge, R., Clarke-Pearson, D. L., Marks, P., McKenzie, S., Yin, S., and Bast, R. C. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res., 50:4087-4091, 1990.
13. Yonemura, Y., Ninoomiya, I., Yamaguchi, A., Fushida, S., Kimura, H., Ohoyama, S., Miyazaki, I., Endou, Y., Tanaka, M., and Sasaki, T. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res., 57:1034-1038,1991.
14. Kern, J. A., Schwartz, D. A., Nordberg, J. E., Weiner, D. B., Greene, M. I., Torney, L., and Robinson, R. A. p185neu” expression in human lung adenocarcinomas predicts shortened survival. Cancer Res., 50: 5184-5191,1990.
15. Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., and Aaronson, S. A. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science (Washington DC), 237:178-182,1986.
16. Hudziak, R. M., Schlessinger, J., and Ullrich, A. Increased expression of the putative growth factor p185 (HER2) causes transformation and tumorigenesis of NIH3T3 cells. Pro. Natl. Acad. Sci. USA, 84:7159-7163,1987.
17. Pierce, J. H., Arnstein, P., DiMarco, E., Artrip, J., Kraus, M. H., Lonardo, F., DiFiore, P. P., and Aaronson, S. A. Oncogenic potential of erbB-2 in human mammary epithelial cells. Oncogene, 6:1189-1194,1991.
18. Yarden, Y., and Ullrich, A. Molecular analysis of signal transduction by growth factors. Biochemistry, 27:3114-3118,1988.
19. Schlessinger, J. The epidermal growth factor receptor as a multifunctional allosteric protein. Biochemistry, 27:3119-3123,1988.
20. Hudziak, R. M., Lewis, G. D., Winget, M., Fendly, B. M., Shepard, H. M., and Ullrich, A. p185neu2 Monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol., 9:1165-1172, 1989.
21. Divgi, C. R., Welt, S., Kris, M., Real, F. X., Yeh, S. D. J., Gralla, R., Merchant, B., Schweighart, S., Unger, M., Larson, S. M., and Mendelsohn, J. Phase I and imaging trial of indium Ill-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J. Natl. Cancer Inst., 83:97-104,1991.
22. Park, J-G., Frucht, H., LaRocca, R. V., Bliss, D. P., Kurita, Y., Chen, T. R., Henslee, J. G., Trepel, J. B., Jensen, R. T., Johnson, B. E., Bang, Y-J., Kim, J-P., and Gazdar, A. Characteristics of cell lines established from human gastric carcinoma. Cancer Res., 50:2773-2780,1990.
23. Mossman, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assays. J. Immunol. Methods, 65: 55-63, 1983.
24. Sibler, W. K., and Eppenberger, U. Quantification of cells cultured on 96-well plates. Anal. Biochem., 182:16-19, 1989.
25. King, C. R., Swain, S. M., Porter, L., Steinberg, S. M., Lippman, M. E., and Gelman, E. P. Heterogeneous expression of erbB-2 messenger RNA in human breast cancer. Cancer Res., 49:4185-4191,1989.
26. Kraus, M. H., Popescu, N. C., Amsbaugh, S. C., and King, C. R. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J., 6:605-610, 1987.
27. Drebin, J. A., Link, V. C., and Greene, M. I. Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene, 2:273-277,1988.
28. White, S., Taetle, R., Seligman, P. A., Rutherford, M., and Trowbridge, I. S. Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects. Cancer Res., 50:6295-6301, 1990.
29. Hancock, M. C., Langton, B. C., Chan, T., Toy, P., Monahan, J. J., Mischak, R. P., and Shawver, L. K. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of ris-diaminedkhloroplatinum against human breast and ovarian tumor cell lines. Cancer Res., 51: 4575-4580, 1991.
30. Kumar, R., Shepard, H. M., and Mendelsohn, J. Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factors) in human mammary carcinoma cells. Mol. Cell. Biol., 77:979-986, 1991.